Validation and application of a high-performance liquid chromatography/tandem mass spectrometry assay for sumatriptan in human plasma |
| |
Authors: | Boulton David W Duncan Glenn F Vachharajani Nimish N |
| |
Affiliation: | Clinical Discovery, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ 08543, USA. david.boulton@bms.com |
| |
Abstract: | A sensitive and convenient high-performance liquid chromatography-tandem mass spectrometry(HPLC-MS/MS) assay is described for the (5-HT(lB/lD)) receptor agonist sumatriptan in human plasma. Sumatriptan was recovered from plasma (81.8 +/- 6.8%) by liquid-liquid extraction. The mobile phase flow rate was 0.3 mL/min and consisted of methanol:water:formic acid (90:10:0.1, v/v/v). The analytical column (4.6 x 100 mm) was packed with Partisil C(8) (5 micro m). The standard curve was linear from 0.7 to 70.4 ng/mL (r(2) > 0.99). The lower limit of quantitation was 0.7 ng/mL. The assay was specific, accurate (percentage deviation from nominal concentrations were <15%), precise and reproducible (within- and between-day coefficients of variation <10.3%). Sumatriptan in plasma was stable over three freeze/thaw cycles and at room temperature for one day. The utility of the assay was demonstrated by following sumatriptan plasma concentrations in two healthy subjects for 8-12 h following a single 20 mg intranasal dose. |
| |
Keywords: | 3‐[2‐(dimethylamine)ethyl]‐N‐methyl‐1H‐indole‐5‐methanesulfonaminde 5‐hydroxytryptamine type 1B and 1D receptors serotonin nasal spray formulation intranasal does pharmacokinetic study |
本文献已被 PubMed 等数据库收录! |